(Q37222860)

English

Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group

scientific article published on 04 December 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1 reference

based on heuristic

inferred from title

Aron Goldhirsch

12

object named as

Aron Goldhirsch

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Lorenzo Gianni

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Shari Gelber

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Alberto Ravaioli

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Karen N Price

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Ilaria Panzini

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Manuela Fantini

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Monica Castiglione-Gertsch

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Olivia Pagani

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Edda Simoncini

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Richard D Gelber

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Alan S Coates

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

4 December 2008

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

European Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

45

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

561-571

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

6 September 2017

Clinical practice. Follow-up of patients with early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

6 September 2017

Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

6 September 2017

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

6 September 2017

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

6 September 2017

Toremifene: an evaluation of its safety profile

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

6 September 2017

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

6 September 2017

Meta-analysis of vascular and neoplastic events associated with tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

6 September 2017

Second cancers after breast cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

6 September 2017

Toxicity of antiestrogens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

6 September 2017

Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

6 September 2017

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

6 September 2017

Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

14 September 2017

Risks of second primary breast and urogenital cancer following female breast cancer in the south of The Netherlands, 1972-2001.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

26 June 2018

Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

26 June 2018

Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

26 June 2018

Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

First--select the target: better choice of adjuvant treatments for breast cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Colorectal cancer following tamoxifen therapy for breast cancer (United States).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

3 September 2018

Risk of second non-hematological malignancies among 376,825 breast cancer survivors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

4 December 2018

Risk of second cancer among women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

4 December 2018

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

4 December 2018

Safety and Efficacy Results of a Randomized Trial Comparing Adjuvant Toremifene and Tamoxifen in Postmenopausal Patients With Node-Positive Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694510

4 December 2018

Cancer risk in women with previous breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19062268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19062268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19062268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second cancers after adjuvant tamoxifen therapy for breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19062268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/19062268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary malignancy after primary female breast cancer in the South of the Netherlands, 1972-2001

1 reference

https://pubmed.ncbi.nlm.nih.gov/19062268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19062268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19062268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19062268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19062268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/19062268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19062268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19062268

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.EJCA.2008.10.011

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37222860&oldid=2092340572"